PT  - JOURNAL ARTICLE
AU  - Katherine Cullen
AU  - Mari Jones
AU  - Rhys D. Pockett
AU  - Anya Burton
AU  - Timothy J.S. Cross
AU  - Ian A. Rowe
AU  - Lizz Paley
AU  - Daniela Tataru
AU  - Graeme Alexander
AU  - Aileen Marshall
AU  - Deborah Fitzsimmons
TI  - Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis
AID  - 10.1136/bmjgast-2022-000998
DP  - 2023 Feb 01
TA  - BMJ Open Gastroenterology
PG  - e000998
VI  - 10
IP  - 1
4099  - http://bmjopengastro.bmj.com//content/10/1/e000998.short
4100  - http://bmjopengastro.bmj.com//content/10/1/e000998.full
SO  - BMJ Open Gastro2023 Feb 01; 10
AB  - Objective Hepatocellular carcinoma (HCC) incidence in the UK trebled between 1997 and 2017. With increasing numbers requiring treatment, understanding the likely impact on healthcare budgets can inform service planning and commissioning. The aim of this analysis was to use existing registry data to describe the direct healthcare costs of current treatments for HCC and estimate the impact on National Health Service (NHS) budgets.Design A retrospective data analysis based on the National Cancer Registration and Analysis Service cancer registry informed a decision-analytic model for England comparing patients by cirrhosis compensation status and those on palliative or curative treatment pathways. Potential cost drivers were investigated by undertaking a series of one-way sensitivity analyses.Results Between 1 January 2010 and 31 December 2016, 15 684 patients were diagnosed with HCC. The median cost per patient over 2 years was £9065 (IQR: £1965 to £20 491), 66% did not receive active therapy. The cost of HCC treatment for England over 5 years was estimated to be £245 million.Conclusion The National Cancer Registration Dataset and linked data sets have enabled a comprehensive analysis of the resource use and costs of secondary and tertiary healthcare for HCC, providing an overview of the economic impact to the NHS England of treating HCC.Data are available upon reasonable request. The data in this study were collected and analyzed under the National Disease Registries Directions 2021, made in accordance with sections 254(1) and 254(6) of the 2012 Health and Social Care Act. This study uses data that has been provided by patients and collected by the NHS as part of their care and support. The data are collated, maintained and quality assured by the National Disease Registration Service, which is part of NHS Digital. https://digital.nhs.uk/ndrs/about/ncras.